<DOC>
	<DOC>NCT02703740</DOC>
	<brief_summary>This study evaluates the injection of a hyaluronic acid dermal filler with lidocaine 0.3% in the treatment of nasolabial folds (NLF). Each patient will receive 1 concentration in a NLF (20 mg/mL) and an other concentration in the other NLF (24 mg/mL).</brief_summary>
	<brief_title>Long Term Safety and Efficacy Assessment of Hyaluronic Acid Dermal Filler With for the Treatment of Nasolabial Folds</brief_title>
	<detailed_description />
	<mesh_term>Lidocaine</mesh_term>
	<mesh_term>Hyaluronic Acid</mesh_term>
	<criteria>Is at least 19 years of age. Has Fitzpatrick Skin Type IV, V, or VI. Has a WSRS score &gt; or = to 3 for both NLF Understands and accepts the obligation not to receive any other procedures or treatments in the nasolabial fold for 6 months Has keloid formation, or hypertrophic scarring or dyschromic scaring. Has hypersensitivity to hyaluronic acid, Chlorhexidine lidocaine or local anaesthetic drugs Has a known bleeding disorder or is receiving drug therapy that could increase the risk of bleeding. Has nasolabial folds that are too severe to be corrected in one treatment session. Has received any dermal filler or other injections, grafting or surgery in either nasolabial fold during the last year. Is pregnant, lactating, or not using acceptable contraception.</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>